FDA Approves Bispecific for Advanced Bile Duct Cancer

Bispecific antibodies surge as next-gen oncology innovation accelerates

BioNTech faces pivotal moment with dual cancer datasets shaping pipeline trajectory

Yzybio-B advances CD3/EpCAM bispecific M701 with new clinical data readouts

Novel oncology candidates expand pipeline momentum across solid tumour targets